Brief: Summit Therapeutics And Lunit Announce Agreement To Apply Ai-Powered Scope Io Platform For Tumor Microenvironment Analysis In Immuno-Oncology Development
BRIEF-Summit Therapeutics And Lunit Announce Agreement To Apply Ai-Powered Scope Io Platform For Tumor Microenvironment Analysis In Immuno-Oncology Development Oct 23 (Reuters) - Lunit Inc. 328130.KQ:
SUMMIT THERAPEUTICS AND LUNIT ANNOUNCE AGREEMENT TO APPLY AI-POWERED SCOPE IO PLATFORM FOR TUMOR MICROENVIRONMENT ANALYSIS IN IMMUNO-ONCOLOGY DEVELOPMENT
Source text: ID:nBw3kD6jRa
Further company coverage: 328130.KQ
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Lunit
See all newsBrief: Summit Therapeutics And Lunit Announce Agreement To Apply Ai-Powered Scope Io Platform For Tumor Microenvironment Analysis In Immuno-Oncology Development
Brief: Lunit Inc To Conduct Capital Increase Of 250 Billion Won
Brief: Lunit Announces Collaboration with Daiichi Sankyo on AI-Driven Biomarker Discovery
Brief: Lunit Inc - Awarded National Tender In France For Breast AI
Brief: Lunit Expands Partnership With Saudi Arabia's Largest Medical Group To Deploy Ai Chest X-Ray Solution